

04-03-01

A BOX/SEQ

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Larg Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
A006 US CONTotal Pages in this Submission  
-126-10/20/40  
U.S. PTO**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

11040 09/82428  
04/02/01**COMMON GAMMA CHAIN BLOCKING AGENTS**

and invented by:

Linda C. Burkly  
 Christopher D. Benjamin  
 Catherine Hession  
 Adrian Whitty

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: 09/189,129

Which is a:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: PCT/US97/07870

Which is a:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: 60/017,466

Enclosed are:

**Application Elements**

1.  Filing fee as calculated and transmitted as described below
2.  Specification having 92 pages and including the following:

- a.  Descriptive Title of the Invention
- b.  Cross References to Related Applications (*if applicable*)
- c.  Statement Regarding Federally-sponsored Research/Development (*if applicable*)
- d.  Reference to Microfiche Appendix (*if applicable*)
- e.  Background of the Invention
- f.  Brief Summary of the Invention
- g.  Brief Description of the Drawings (*if drawings filed*)
- h.  Detailed Description
- i.  Claim(s) as Classified Below
- j.  Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
**A006 US CON**

Total Pages in this Submission  
**-126-**

**Application Elements (Continu d)**

3.  Drawing(s) (*when necessary as prescribed by 35 USC 113*)  
a.  Formal Number of Sheets -14-  
b.  Informal Number of Sheets \_\_\_\_\_

4.  Oath or Declaration  
a.  Newly executed (*original or copy*)  Unexecuted  
b.  Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)  
c.  With Power of Attorney  Without Power of Attorney  
d.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5.  Incorporation By Reference (*usable if Box 4b is checked*)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under  
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.

6.  Computer Program in Microfiche (*Appendix*)

7.  Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all must be included*)  
a.  Paper Copy  
b.  Computer Readable Copy (*identical to computer copy*)  
c.  Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8.  Assignment Papers (*cover sheet & document(s)*)

9.  37 CFR 3.73(B) Statement (*when there is an assignee*)

10.  English Translation Document (*if applicable*)

11.  Information Disclosure Statement/PTO-1449  Copies of IDS Citations

12.  Preliminary Amendment

13.  Acknowledgment postcard

14.  Certificate of Mailing

First Class  Express Mail (*Specify Label No.:*) EL 798593110 US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
**A006 US CON**

Total Pages in this Submission  
**-126-**

**Accompanying Application Parts (Continued)**

15.  Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16.  Additional Enclosures *(please identify below):*



**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

17.  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

*An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.*

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
A006 US CON

Total Pages in this Submission  
-126-

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
<b>Total Claims</b>	58	- 20 =	38	x \$18.00	\$684.00
<b>Indep. Claims</b>	15	- 3 =	12	x \$80.00	\$960.00
<b>Multiple Dependent Claims (check if applicable)</b>					\$0.00
				<b>BASIC FEE</b>	\$710.00
<b>OTHER FEE (specify purpose)</b>					\$0.00
				<b>TOTAL FILING FEE</b>	\$2,354.00

A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge and credit Deposit Account No. **02-2327** as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of **\$2,354.00** as filing fee.

Credit any overpayment.

Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



*Signature*

Dated: **April 2, 2001**

**Niki D. Cox**  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
Telephone: (617) 679-2079

CC:

Docket: A006US CON

**IN THE UNITED STATES RECEIVING OFFICE**

In re application of: Burkly, et al.

U.S. Serial No.: Not yet assigned

U.S. Filing date: Herewith

Continuation of  
Serial No.: 09/189,129

Continuation-in-part of  
prior application: 60/017,466

International Filing Date:  
PCT/US97/07870 09 May 1997


For: COMMON GAMMA CHAIN BLOCKING AGENTS

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence, together with all items referred to herein, is being deposited with the United States Post Office as Express Mail Label No. EL798593110US in an Express Mail Envelope addressed to BOX PATENT APPLICATION, Commissioner for Patents, Washington, DC 20231 on the date shown below.

2 April 2001

Date



Patricia Hofstetter

**STATEMENT REGARDING NUCLEOTIDE  
AMINO ACID SEQUENCE LISTING**

Box Patent Applications  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith is a diskette containing a machine readable copy of the Sequence Listing set forth on pages 77 to 85 of the Paper Sequence listing for the above-referenced Patent Application as filed herewith.

The content of the Sequence Listing diskette submitted herewith are the same as the contents of the paper form of the Sequence Listing submitted herewith.

If there are any questions, please contact the undersigned by telephone.

Respectfully submitted,

Date: April 2, 2001

Niki Cox  
Niki D. Cox  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.1)**


Applicant(s): Burkly, et al.

Docket No.

A006 US CON

Serial No. Not yet assigned	Filing Date Herewith	Examiner To be Assigned	Group Art Unit To be Assigned
--------------------------------	-------------------------	----------------------------	----------------------------------

Invention:

**COMMON GAMMA CHAIN BLOCKING AGENTS**

I hereby certify that this Continuation Utility Patent Application; Declaration/Power of Attorney  
Statement Re: Sequence Listing; Paper copy (*Identify type of correspondence*)  
Sequence on Diskette:  
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  
April 2, 2001  
(Date)

**Patricia Hofstetter***(Typed or Printed Name of Person Mailing Correspondence)*

A handwritten signature of Patricia Hofstetter is written over the typed name.

*(Signature of Person Mailing Correspondence)*EL798593110US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**